Assessing the Impact of Psychosocial Support and Pharmacological Interventions on Medication Adherence in Patients with Laboratory-Confirmed Chronic Illnesses: A Multidisciplinary Approach

Ohoud M. Albedeiwy¹, Shaheinaz A. Alkahtani², Saud N. Alshammary³, Shaikha N. Binsunbel⁴, Asrar I. Alshomrani⁵, Tahani M. Alsalmi⁶, Mohammed H. Khubrani⁷, Abdullah M. Alghamdi⁸, Jehan H. Ben Hyzaam⁹, Fahad M. Aljuraid¹⁰

Health Affairs at the Ministry of National Guard

Abstract

Background: Medication adherence is a critical factor in managing chronic illnesses, yet many patients fail to adhere to prescribed treatments due to psychosocial and practical barriers. This study evaluates the impact of a multidisciplinary approach, combining psychosocial support, pharmacotherapy, and nursing care, on improving medication adherence and clinical outcomes in patients with laboratory-confirmed chronic illnesses.

Methods: A quasi-experimental study was conducted at a tertiary hospital with 200 patients diagnosed with chronic illnesses (diabetes and hyperlipidemia). The intervention group (n=100) received psychosocial counseling, pharmacotherapy, and nursing care, while the control group (n=100) received standard pharmacotherapy and nursing care. Medication adherence, psychosocial well-being (anxiety, depression, stress), and clinical outcomes (HbA1c, cholesterol levels) were assessed at baseline, 3 months, and 6 months.

Results: The intervention group showed significant improvements in medication adherence (p=0.001), anxiety (p=0.007), depression (p=0.012), and stress levels (p=0.004) compared to the control group. Clinical outcomes, including HbA1c (p=0.021) and total cholesterol (p=0.017), also improved significantly in the intervention group.

Conclusion: The multidisciplinary approach, integrating psychosocial support with pharmacotherapy and nursing care, significantly enhances medication adherence and clinical outcomes in patients with chronic illnesses. This model should be considered for broader implementation in chronic disease management.

Keywords: Medication Adherence, Psychosocial Support, Pharmacotherapy, Nursing Care, Chronic Illness, Diabetes, Hyperlipidemia, Multidisciplinary Care

Introduction

Chronic illnesses, such as diabetes and hyperlipidemia, are among the leading causes of morbidity and mortality worldwide, requiring long-term management through lifestyle changes and medication adherence (World Health Organization, 2014). Effective treatment of these conditions depends on patients consistently

adhering to prescribed medications. However, non-adherence to medications is a widespread issue, with approximately 50% of patients with chronic conditions failing to take their medications as prescribed (Brown & Bussell, 2011). This lack of adherence leads to poor health outcomes, increased hospitalizations, and higher healthcare costs (Sabate, 2003).

Medication adherence is influenced by several factors, including the complexity of the medication regimen, side effects, and a patient's understanding of their illness (Nieuwlaat et al., 2014). Psychosocial factors, such as anxiety, depression, and stress, also play a significant role in determining whether a patient adheres to their treatment plan. Studies have shown that patients with high levels of stress or untreated mental health conditions are less likely to follow their prescribed medication regimens (DiMatteo, Lepper, & Croghan, 2000).

Pharmacists and nurses are critical in supporting patients with chronic illnesses through medication management and ongoing care. Pharmacists play an essential role in educating patients about their medications, addressing concerns about side effects, and ensuring that medications are used safely and effectively (Buxton et al., 2015). Nurses provide continued support through patient follow-up, reinforcing education, and monitoring patient progress. Despite these efforts, the integration of psychosocial support, particularly from psychologists, in managing chronic illnesses remains underutilized.

This study aims to evaluate the combined effects of psychosocial support, pharmacotherapy, and nursing care on medication adherence in patients with laboratory-confirmed chronic illnesses. By assessing how a multidisciplinary approach involving psychologists, pharmacists, and nurses can enhance medication adherence, this research seeks to provide insights into more comprehensive care strategies for managing chronic conditions.

Literature Review

Chronic Illnesses and Medication Adherence

Chronic illnesses, such as diabetes and hyperlipidemia, require long-term management, often involving multiple medications. Medication adherence, defined as the extent to which a patient's behavior matches agreed recommendations from a healthcare provider, is critical for the effective management of these conditions (Sabate, 2003). Despite the importance of adherence, research shows that only about 50% of patients with chronic illnesses take their medications as prescribed, leading to poor disease control and increased risk of complications (Brown & Bussell, 2011).

Non-adherence to medication regimens is linked to various factors, including the complexity of the regimen, forgetfulness, and side effects. However, more nuanced factors, such as patient beliefs about their illness and treatment, have also been identified as significant contributors to non-adherence (Horne et al., 2013). These factors underscore the need for comprehensive care approaches that go beyond medication prescriptions to address the psychosocial aspects of chronic disease management.

Psychosocial Barriers to Medication Adherence

Psychosocial factors, such as anxiety, depression, and stress, have been shown to significantly impact a patient's ability to adhere to long-term therapies. Patients experiencing these psychological challenges often struggle to maintain consistent medication use, either due to a lack of motivation, emotional fatigue, or cognitive difficulties (DiMatteo et al., 2000). Depression, in particular, is a well-established risk factor for medication non-adherence. A meta-analysis by DiMatteo et al. (2000) found that patients with depression

were three times more likely to be non-adherent to their prescribed treatments than those without depression.

Psychosocial support from psychologists can help address these barriers by providing patients with coping strategies to manage their mental health and improve their adherence to treatment. Cognitive-behavioral therapy (CBT), stress management, and counseling have been effective in reducing anxiety and depression, thereby improving adherence rates (Haskard-Zolnierek&DiMatteo, 2009). Research suggests that integrating psychological counseling into chronic illness care is an underutilized strategy that could significantly enhance patient outcomes (Ho et al., 2017).

Pharmacological Interventions and Patient Education

Pharmacists play a crucial role in ensuring medication adherence by providing patient education, conducting medication reconciliation, and addressing concerns about side effects. Pharmacists are often at the frontline of patient care, offering counseling on proper medication use and strategies to overcome common barriers to adherence, such as forgetfulness or misunderstanding of the treatment regimen (Buxton et al., 2015).

Studies have shown that pharmacist-led interventions can significantly improve medication adherence. For example, a systematic review by Chisholm-Burns et al. (2010) found that pharmacist involvement in direct patient care, including medication management and patient education, improved medication adherence and clinical outcomes in patients with chronic diseases. Pharmacists also help patients understand the importance of adherence by explaining the consequences of missing doses, which is particularly important for conditions like diabetes and hyperlipidemia, where non-adherence can lead to severe complications (Garber et al., 2017).

Nursing Care and Chronic Disease Management

Nurses play an essential role in supporting patients with chronic diseases through follow-up care, patient education, and emotional support. As primary caregivers, nurses often have the most contact with patients, allowing them to identify adherence issues early and provide ongoing support to ensure patients follow their treatment plans (Adolfsson et al., 2004). In chronic disease management, nurses educate patients about the importance of medication adherence, help them develop self-management skills, and provide emotional support to encourage long-term compliance.

Studies have shown that nurse-led interventions, particularly those involving frequent patient contact and education, can improve adherence to treatment in patients with chronic diseases (Riegel et al., 2016). Nurses are also well-positioned to identify psychosocial factors that may be affecting a patient's adherence and can collaborate with psychologists and pharmacists to address these barriers.

Multidisciplinary Approaches to Improving Medication Adherence

Recent research highlights the effectiveness of multidisciplinary care models in improving medication adherence and overall patient outcomes. Multidisciplinary teams, which may include pharmacists, nurses, psychologists, and laboratory technologists, provide comprehensive care that addresses the medical, psychological, and social factors affecting patients with chronic illnesses. These teams work together to ensure that patients understand their treatment, receive consistent support, and have access to resources that promote adherence.

For example, a study by Tricco et al. (2014) found that multidisciplinary interventions, involving both psychosocial support and medication management, improved adherence rates in patients with chronic

3

illnesses. The study emphasized the importance of communication and collaboration between healthcare professionals in addressing the multiple factors that contribute to non-adherence. By involving psychologists, pharmacists, and nurses in the care of patients with chronic illnesses, multidisciplinary teams can provide more holistic care that meets both the physical and emotional needs of patients.

Gaps in the Literature

While existing research supports the effectiveness of psychosocial support and pharmacological interventions in improving medication adherence, few studies have examined how these interventions work together in a multidisciplinary model. Specifically, there is limited research exploring the combined effects of psychological counseling, pharmacist-led medication management, and nursing care on medication adherence in patients with laboratory-confirmed chronic illnesses. This gap highlights the need for further investigation into how a collaborative approach can optimize adherence and improve clinical outcomes.

Methodology

Study Design

This study employed a quasi-experimental design to assess the impact of psychosocial support, pharmacological interventions, and nursing care on medication adherence in patients with laboratory-confirmed chronic illnesses. Participants were divided into two groups: an intervention group that received psychosocial support in addition to standard pharmacotherapy and nursing care, and a control group that received standard pharmacotherapy and nursing care alone.

Setting

The study was conducted at a large tertiary care hospital that provides specialized care for patients with chronic illnesses such as diabetes and hyperlipidemia. The study took place in collaboration with the hospital's outpatient chronic disease management clinic.

Participants

Participants were recruited from the hospital's outpatient department. Eligible participants were identified through laboratory testing that confirmed the diagnosis of chronic illnesses, such as elevated HbA1c for diabetes and abnormal lipid profiles for hyperlipidemia.

- Inclusion Criteria:

- Adults aged 18 years and older.

- Patients with laboratory-confirmed chronic illnesses (e.g., HbA1c \geq 7.0% for diabetes, total cholesterol \geq 200 mg/dL for hyperlipidemia).

- Patients prescribed long-term medication regimens for their condition.

- Patients able to provide informed consent and commit to follow-up assessments.

- Exclusion Criteria:

- Patients with severe psychiatric conditions that could interfere with participation in psychosocial counseling.

- Patients with terminal illnesses requiring palliative care.

- Patients with cognitive impairments or language barriers preventing participation in counseling sessions.

A total of 200 patients were enrolled in the study, with 100 assigned to the intervention group and 100 to the control group using non-randomized sampling based on availability and willingness to participate in the psychosocial support program.

Intervention

The intervention group received a combination of psychosocial support, pharmacotherapy, and nursing care, while the control group received pharmacotherapy and nursing care alone.

1. Psychosocial Support:

- Participants in the intervention group received bi-weekly psychosocial counseling sessions with a psychologist over a period of 6 months. The counseling sessions focused on cognitive-behavioral techniques (CBT) to help patients manage stress, anxiety, and depression related to their chronic illness.

- Topics covered in counseling included coping with disease burden, building motivation for medication adherence, and stress reduction techniques.

2. Pharmacotherapy:

- Both groups received standard pharmacological treatment for their conditions, managed by a pharmacist. The pharmacist provided medication reconciliation, patient education on medication adherence, and monitored potential side effects.

- Pharmacists in the intervention group reinforced adherence education during monthly follow-up visits, while those in the control group received standard medication counseling during their routine check-ups.

3. Nursing Care:

- Nurses in both groups provided routine follow-up care, including monitoring vital signs, assessing adherence to medications, and offering emotional support. Nurses in the intervention group were also trained to reinforce the psychosocial interventions provided by the psychologist by checking in on patients ' emotional well-being during follow-ups.

Data Collection

Data were collected at three time points: baseline (pre-intervention), 3 months, and 6 months. The following data were gathered:

1. Medication Adherence:

- Adherence to prescribed medications was measured using the Morisky Medication Adherence Scale (MMAS-8). Scores on this validated scale range from 0 to 8, with higher scores indicating better adherence. Adherence was assessed at baseline, 3 months, and 6 months.

2. Psychosocial Measures:

- Anxiety and depression levels were assessed using the Hospital Anxiety and Depression Scale (HADS) at baseline, 3 months, and 6 months to monitor improvements in mental health following psychosocial interventions.

- The Perceived Stress Scale (PSS) was used to measure patients 'stress levels at the same intervals.

3. Clinical Outcomes:

Volume 7 Issue 4

- Laboratory data, including HbA1c levels for patients with diabetes and total cholesterol for patients with hyperlipidemia, were collected at baseline and 6 months to evaluate the clinical impact of improved medication adherence.

- Blood pressure and body mass index (BMI) were also monitored as secondary clinical indicators of treatment effectiveness.

Data Analysis

Data were analyzed using both quantitative and qualitative methods.

1. Quantitative Analysis:

- Descriptive statistics were used to summarize the demographic characteristics of the participants.

- Repeated-measures ANOVA was conducted to compare medication adherence scores (MMAS-8) between the intervention and control groups over time (baseline, 3 months, and 6 months).

- Changes in psychosocial measures (HADS, PSS) and clinical outcomes (HbA1c, cholesterol levels) were analyzed using paired t-tests to assess within-group improvements and independent t-tests to compare differences between groups.

- Multivariate regression was used to explore the association between psychosocial support and medication adherence, controlling for potential confounding factors such as age, gender, and baseline anxiety levels.

2. Qualitative Analysis (if applicable):

- Semi-structured interviews were conducted with 20 participants from the intervention group to explore their experiences with psychosocial counseling and how it influenced their medication adherence. Interviews were transcribed and analyzed using thematic analysis to identify key themes related to the psychological and emotional benefits of the intervention.

Ethical Considerations

Ethical approval for the study was obtained from the Ethics Committee. Written informed consent was obtained from all participants before enrollment. Patient confidentiality was maintained throughout the study by anonymizing data, and all information was stored securely. Participants were informed that they could withdraw from the study at any time without affecting their standard care.

Trustworthiness

To ensure the trustworthiness of the study:

- Credibility: Triangulation of data sources (e.g., self-reported adherence, clinical outcomes, and psychosocial measures) was used to confirm the findings.

- Dependability: A detailed audit trail documenting all research procedures was maintained to allow replication of the study.

- Transferability: Thick descriptions of the intervention, setting, and participants were provided to allow for the applicability of findings to other settings.

- Confirmability: Reflexive notes were maintained by the research team to account for any potential biases in data interpretation, particularly during the qualitative analysis.

Findings

This study assessed the impact of psychosocial support, pharmacotherapy, and nursing care on medication adherence in patients with laboratory-confirmed chronic illnesses. Data were collected at baseline, 3

months, and 6 months post-intervention. The findings are presented in two parts: (1) quantitative results on medication adherence, psychosocial measures, and clinical outcomes; and (2) qualitative insights from participant interviews on the impact of psychosocial counseling.

Quantitative Findings

Outcome	Intervention Group	Control Group	P-value
	(n=100)	(n=100)	
Medication			
Adherence (MMAS-			
8)			
Baseline	4.7 ±1.5	4.8 ±1.4	0.82
3 Months	6.5 ±1.2	5.1 ±1.3	0.002
6 Months	7.2 ±1.0	5.3 ±1.4	0.001
Anxiety (HADS-			
Anxiety)			
Baseline	11.2 ±3.4	11.5 ±3.5	0.65
6 Months	7.8 ±2.9	10.5 ±3.6	0.007
Depression (HADS-			
Depression)			
Baseline	10.5 ±3.2	10.2 ±3.3	0.74
6 Months	7.3 ±3.0	9.7 ±3.4	0.012
Stress (PSS)			
Baseline	23.5 ±4.9	24.2 ±5.1	0.58
6 Months	18.1 ±4.2	22.9 ±4.7	0.004
HbA1c (%)			
Baseline	8.1 ±1.5	8.0 ±1.6	0.79
6 Months	6.8 ±1.3	7.4 ±1.4	0.021
Total Cholesterol			
(mg/dL)			
Baseline	220.5 ±25.3	219.7 ±26.0	0.82
6 Months	190.2 ±22.8	205.3 ±24.9	0.017

Table 1: Medication	Adherence, I	Psychosocial	Measures.	and Clinical	Outcomes
Table 1. Medication	Aunci chec, i	i sychosociai	micasui cs,	and Chincar	Outcomes

P-value < 0.05 indicates statistical significance.

Medication Adherence

- Baseline: At baseline, there were no significant differences in medication adherence (MMAS-8) between the intervention group (mean score = 4.7) and the control group (mean score = 4.8).

- 3 Months: After 3 months, the intervention group, which received psychosocial support in addition to pharmacotherapy and nursing care, showed a significantly higher adherence score (6.5) compared to the control group (5.1) (p=0.002).

- 6 Months: By 6 months, medication adherence continued to improve in the intervention group (mean score = 7.2), while the control group showed only a modest increase (mean score = 5.3) (p=0.001).

Psychosocial Measures

- Anxiety (HADS): Anxiety scores significantly decreased in the intervention group, from a baseline mean of 11.2 to 7.8 at 6 months, compared to a smaller reduction in the control group (p=0.007).

- Depression (HADS): Depression scores also significantly improved in the intervention group, from 10.5 at baseline to 7.3 at 6 months, while the control group showed less improvement (p=0.012).

- Stress (PSS): Stress levels decreased significantly in the intervention group over 6 months (p=0.004), reflecting the positive impact of psychosocial counseling.

Clinical Outcomes

- HbA1c: The intervention group saw a significant reduction in HbA1c levels at 6 months (6.8% from a baseline of 8.1%), indicating better blood sugar control, compared to the control group (p=0.021).

- Total Cholesterol: Similarly, total cholesterol levels dropped more significantly in the intervention group (from 220.5 to 190.2 mg/dL) compared to the control group (p=0.017), reflecting better lipid management.

Qualitative Findings

Semi-structured interviews were conducted with 20 participants from the intervention group to explore their experiences with psychosocial counseling and its impact on medication adherence. Thematic analysis revealed three major themes: (1) Emotional Support and Motivation, (2) Improved Understanding of Disease Management, and (3) Overcoming Barriers to Medication Adherence.

Theme 1: Emotional Support and Motivation

Many participants expressed that the psychosocial counseling sessions provided emotional support that motivated them to adhere to their medication regimen. They reported feeling more capable of managing their condition after addressing underlying anxiety and stress.

- Participant 8 (Diabetes Patient):

"The counseling sessions helped me focus not just on taking my medicine, but also on why it's important. I realized how my stress was making it harder to stay on track."

Theme 2: Improved Understanding of Disease Management

Participants noted that the combination of psychological counseling and pharmacist interventions improved their understanding of how their medication worked, which increased their commitment to adhering to treatment.

- Participant 15 (Hyperlipidemia Patient):

"I used to take my pills without really understanding what they did. After talking with the psychologist and pharmacist, I felt more in control and motivated to keep going."

Theme 3: Overcoming Barriers to Medication Adherence

Several participants highlighted how the counseling helped them overcome practical barriers to adherence, such as forgetfulness and low motivation. Participants felt more empowered to manage their medication schedule after learning coping strategies for dealing with stress and anxiety.

- Participant 3 (Diabetes Patient):

"Before, I would forget to take my meds all the time. Now, I'm more organized, and I use the techniques I learned in the sessions to stay on top of it."

Discussion

This study aimed to assess the impact of a multidisciplinary intervention—combining psychosocial support, pharmacotherapy, and nursing care—on medication adherence in patients with laboratory-confirmed chronic illnesses, such as diabetes and hyperlipidemia. The findings reveal significant improvements in medication adherence, psychosocial well-being, and clinical outcomes in the intervention group, demonstrating the effectiveness of a comprehensive care approach for managing chronic diseases.

Improvement in Medication Adherence

The results showed a significant increase in medication adherence in the intervention group, where participants received psychosocial counseling, compared to the control group. At 3 months, adherence scores (MMAS-8) in the intervention group were significantly higher (6.5) compared to the control group (5.1), with further improvements observed at 6 months (7.2 vs. 5.3, p=0.001). This indicates that psychosocial support, when integrated with pharmacotherapy and nursing care, plays a critical role in motivating patients to adhere to their medication regimens.

These findings align with existing research that suggests psychosocial factors, such as anxiety, stress, and depression, can negatively impact medication adherence (DiMatteo et al., 2000). By addressing these emotional and psychological barriers through counseling, patients in the intervention group were better equipped to manage their chronic conditions and stay committed to their treatment plans. Previous studies have also highlighted the importance of psychological counseling in improving self-efficacy and motivation for chronic disease management (Haskard-Zolnierek&DiMatteo, 2009). This study supports these findings by demonstrating that targeted psychosocial interventions can significantly enhance adherence.

Reduction in Anxiety, Depression, and Stress

The psychosocial support provided in the intervention group not only improved medication adherence but also led to significant reductions in anxiety, depression, and stress levels. By 6 months, anxiety scores (HADS) had dropped significantly in the intervention group (7.8) compared to the control group (10.5, p=0.007), with similar improvements seen in depression and stress levels (p=0.012 and p=0.004, respectively).

These findings underscore the importance of addressing mental health in chronic disease management. Patients with chronic illnesses often experience heightened levels of stress and anxiety, which can impair their ability to follow prescribed treatments. The psychological counseling sessions in this study focused on helping patients cope with the emotional burdens of living with a chronic condition, which in turn improved their adherence to medication. The strong correlation between improved mental health and better treatment adherence reinforces the need for mental health support to be integrated into chronic disease care (Ho et al., 2017).

Clinical Outcomes and Disease Management

The intervention group not only showed improvements in adherence and mental health but also experienced better clinical outcomes. For diabetes patients, HbA1c levels significantly decreased in the intervention group (from 8.1% to 6.8%), reflecting better blood sugar control, compared to the control group (7.4%, p=0.021). Similarly, patients with hyperlipidemia in the intervention group had significantly lower total cholesterol levels (from 220.5 mg/dL to 190.2 mg/dL) compared to the control group (p=0.017).

These results suggest that improved medication adherence, driven by psychosocial support and comprehensive care, directly impacts disease control and overall health outcomes. The findings are consistent with previous research that highlights the positive impact of pharmacist-led medication management and psychosocial support on clinical outcomes in chronic disease management (Chisholm-Burns et al., 2010). By ensuring that patients are mentally prepared to follow their treatment regimens, this multidisciplinary approach can lead to more effective disease management and a reduction in long-term complications.

The Role of Multidisciplinary Care in Enhancing Adherence

The multidisciplinary approach used in this study, which included psychologists, pharmacists, and nurses, proved to be an effective strategy for improving medication adherence and overall patient outcomes. Pharmacists played a critical role in educating patients about their medications, while nurses provided continuous follow-up care. The addition of psychosocial counseling addressed the emotional and psychological aspects of adherence, creating a holistic care model that improved both mental health and clinical outcomes.

This finding is in line with previous studies that emphasize the importance of multidisciplinary care models in chronic disease management (Tricco et al., 2014). The integration of psychological counseling into traditional care models is often overlooked, despite its proven benefits. This study demonstrates that combining medical, psychological, and nursing interventions is essential for addressing the complex challenges faced by patients with chronic illnesses.

Challenges and Limitations

While the study demonstrated positive outcomes, there are several limitations to consider. First, the study was conducted at a single tertiary hospital, which may limit the generalizability of the findings to other healthcare settings. Future studies should consider multi-center trials to validate these results in different contexts. Additionally, while the study followed patients for 6 months, longer follow-up periods are needed to assess the sustainability of the improvements in adherence and clinical outcomes over time.

Another limitation is the reliance on self-reported adherence data using the MMAS-8 scale, which may be subject to reporting bias. Although this scale is widely used and validated, future studies could incorporate more objective measures of adherence, such as prescription refill data or electronic pill counts, to provide a more accurate assessment.

Implications for Practice

The findings of this study have important implications for clinical practice, particularly in the management of chronic diseases. First, healthcare providers should consider incorporating psychosocial support into routine care for patients with chronic illnesses. This could involve employing psychologists or mental health professionals to work alongside pharmacists and nurses in multidisciplinary care teams.

Second, this study highlights the need for healthcare systems to provide comprehensive, patient-centered care that addresses both the physical and mental aspects of disease management. By offering psychosocial counseling alongside pharmacotherapy and nursing care, healthcare providers can improve medication adherence, enhance patient outcomes, and reduce the long-term burden of chronic diseases.

Future Research

Future research should focus on expanding the study to include a larger and more diverse patient population. Additionally, further studies should explore the cost-effectiveness of integrating psychosocial support into chronic disease management, as this approach may reduce healthcare costs by preventing hospitalizations and complications. Long-term studies are also needed to assess the durability of the improvements in adherence and clinical outcomes observed in this study.

Conclusion

This study demonstrates that a multidisciplinary approach, combining psychosocial support, pharmacotherapy, and nursing care, significantly improves medication adherence, reduces anxiety and stress, and leads to better clinical outcomes in patients with laboratory-confirmed chronic illnesses. By addressing both the mental and physical aspects of chronic disease management, this comprehensive care model provides a promising solution to the challenges of long-term treatment adherence.

References

- 1. Adolfsson, E. T., Smide, B., Gregeby, E., Fernström, L., &Wikblad, K. (2004). Implementing empowerment group education in diabetes. *Patient education and counseling*, *53*(3), 319-324.
- Buxton, J. A., Babbitt, R., Clegg, C. A., Durley, S. F., Epplen, K. T., Marsden, L. M., ... & Thompson, N. S. (2015). ASHP guidelines: minimum standard for ambulatory care pharmacy practice. *American Journal of Health-System Pharmacy*, 72(14), 1221-1236.
- 3. Brown, M. T., & Bussell, J. K. (2011, April). Medication adherence: WHO cares?. In *Mayo clinic proceedings* (Vol. 86, No. 4, pp. 304-314). Elsevier.
- Chisholm-Burns, M. A., Lee, J. K., Spivey, C. A., Slack, M., Herrier, R. N., Hall-Lipsy, E., ... &Wunz, T. (2010). US pharmacists' effect as team members on patient care: systematic review and metaanalyses. *Medical care*, 48(10), 923-933.
- 5. DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Archives of internal medicine*, *160*(14), 2101-2107.
- Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., ... &Umpierrez, G. E. (2017). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2017 executive summary. *Endocrine Practice*, 23(2), 207-238.
- Horne, R., Chapman, S. C., Parham, R., Freemantle, N., Forbes, A., & Cooper, V. (2013). Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. *PloS one*, 8(12), e80633.
- 8. Ho, J., McWilliams, A., Emery, J., Saunders, C., Reid, C., Robinson, S., & Brims, F. (2017). Integrated care for resected early stage lung cancer: innovations and exploring patient needs. *BMJ Open Respiratory Research*, 4(1), e000175.
- Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., ... & Haynes, R. B. (2014). Interventions for enhancing medication adherence. *Cochrane database of systematic reviews*, (11).
- 10. Riegel, B., Dickson, V. V., & Faulkner, K. M. (2016). The situation-specific theory of heart failure selfcare: revised and updated. *Journal of Cardiovascular Nursing*, *31*(3), 226-235.
- 11. Sabaté, E. (Ed.). (2003). Adherence to long-term therapies: evidence for action. World Health Organization.
- 12. Tricco, A. C., Antony, J., Ivers, N. M., Ashoor, H. M., Khan, P. A., Blondal, E., ... & Straus, S. E. (2014). Effectiveness of quality improvement strategies for coordination of care to reduce use of health care services: a systematic review and meta-analysis. *Cmaj*, *186*(15), E568-E578.

- 13. World Health Organization. (2014). Global status report on noncommunicable diseases 2014.
- 14. Zolnierek, K. B. H., &DiMatteo, M. R. (2009). Physician communication and patient adherence to treatment: a meta-analysis. *Medical care*, 47(8), 826-834.

12